Canada blocks bulk exports of certain prescription drugs in response to Trump’s import plan

OTTAWA (Reuters) – Canada on Saturday blocked bulk exports of prescription drugs if they created a shortage in the country, in response to efforts by outgoing U.S. President Donald Trump to allow imports from Canada to cut prices by some drugs for Americans.

“Certain drugs destined for the Canadian market are prohibited from distribution for consumption outside Canada if that sale results in or aggravates a drug shortage,” Health Minister Patty Hajdu said in a statement.

“Companies will now also be required to provide information to assess existing or potential shortages, upon request, and within 24 hours in the event of a serious or imminent health risk,” the statement said.

The Canadian measure came into effect on Friday, just days before an American “Import Prescription Drugs” rule that would eventually allow authorized American pharmacists or wholesalers to import certain prescription drugs intended for the Canadian market in bulk.

Neither the White House nor the Department of Health and Human Services received an immediate response to a request for comment.

Trump touted the plan during his first debate with President-elect Joe Biden, who also said during his campaign that he would put in place a similar import plan to try to cut prescription drug costs for Americans.

“Canada is a small market, accounting for 2% of global drug sales, which purchases 68% of its drugs internationally. The need for vigilance to maintain the national drug supply continues, ”the statement said.

Canadian Prime Minister Justin Trudeau said in September that he was ready to help other countries with pharmaceutical supplies if possible, adding that his priority was to protect the needs of Canadians.

Many of Canada’s drug suppliers have opposed Trump’s plan, saying it could lead to shortages.